Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2007-06-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The measurements will be performed under sedation at different levels of PEEP. The following groups will be included: a) control patients withot lung injury and brain injury; b) brain injured patients without lung injury within the first 72 hours; c) brain injured patients without lung injury after 72 hours; d) brain injured patients with lung injury. Brain injury was defined as primary or secondary. Respiratory functional data will be related to intra-abdominal pressure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Patients without lung injury and brain injury
PEEP
Application of positive end expiratory pressure
Brain No ALI 1
Patients with brain injury and no lung injury within 72 hours from ICU entry
PEEP
Application of positive end-expiratory pressure
Brain No ALI 2
Patients with brain injury and no ALI after 72 hours from ICU entry
PEEP
Application of positive end-expiratory pressure
Brain ALI
Patients with brain injury and Acute Lung Injury (ALI)
PEEP
Application of positive end-expiratory pressure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEEP
Application of positive end expiratory pressure
PEEP
Application of positive end-expiratory pressure
PEEP
Application of positive end-expiratory pressure
PEEP
Application of positive end-expiratory pressure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 yrs
* Mechanical ventilation
* No smoker
* No lung injury at entry
* Brain injury (traumatic or postoperative or spontaneous bleeding) in brain injury group
Exclusion Criteria
* Hemodynamic instability
* Immunodepression
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università degli Studi dell'Insubria
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Insubria Varese, Italy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paolo Pelosi, MD
Role: PRINCIPAL_INVESTIGATOR
University of Insubria, Varese
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedale di Circolo e Fondazione Macchi
Varese, Varese, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Paolo Severgnini, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
No financial support
Identifier Type: -
Identifier Source: secondary_id
003
Identifier Type: -
Identifier Source: org_study_id